{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T12:11:59Z","timestamp":1769083919102,"version":"3.49.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"vor","delay-in-days":1549,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T00:00:00Z","timestamp":1632355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>In previous randomized controlled trials, the use of tolvaptan (TLV) at a fixed dose of 30 mg\/day for 1 year did not provide renal benefits in patients with heart failure (HF). This retrospective, cohort study examined the renoprotective effects of long-term, flexible-dose, and lower-dose TLV use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Tolvaptan users were defined as patients receiving TLV for at least 180 consecutive days or those who continued it until death, any cardiac events, or renal replacement therapy even if it was taken for &amp;lt;180 days. Of a total of 584 HF patients, 78 TLV users were identified. The median age, baseline B-type natriuretic peptide, and estimated glomerular filtration rate (eGFR) were 71 years, 243 pg\/mL, and 54 mL\/min\/1.73 m2, respectively. During follow-up (median, 461 days), TLV use (median average dose, 7.5 mg\/day) was associated with frequent dose reductions of loop diuretics (incidence rate ratio [IRR], 1.5; 95% confidence interval [CI], 1.1\u20132.2), particularly in patients with serum sodium \u2264135 mEq\/L (IRR, 2.9; 95% CI, 1.5\u20135.7) (Pinteraction = 0.04). In a mixed effects model, propensity score (PS)-matched TLV users had higher eGFRs over time than PS-matched never-users (P &amp;lt; 0.01). The entire cohort analyses (N = 584) yielded similar results. The renal benefit of TLV in terms of annualized eGFR slope was more pronounced in patients with lower sodium levels (Pinteraction = 0.03). This effect modification was extinguished when patients who underwent a loop diuretic dose reduction during the follow-up period were excluded from the analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Long-term, flexible-dose, and low-dose TLV use was associated with better renal function, particularly in hyponatremic HF, possibly due to its loop diuretic dose-sparing effect in the long term.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.13507","type":"journal-article","created":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T13:31:58Z","timestamp":1632403918000},"page":"4904-4914","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Renoprotection by Long-Term Low-Dose Tolvaptan in Patients with Heart Failure and Hyponatremia"],"prefix":"10.1093","volume":"8","author":[{"given":"Tatsufumi","family":"Oka","sequence":"first","affiliation":[{"name":"Department of Nephrology, Osaka University Graduate School of Medicine , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Hamano","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Osaka University Graduate School of Medicine , Osaka ,","place":["Japan"]},{"name":"Department of Nephrology, Nagoya City University Graduate School of Medical Sciences , 1, Azakawasumi, Mizuho-cho, Mizuho-ku, Aichi, Nagoya, 467-8602 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohito","family":"Ohtani","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Doi","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Osaka University Graduate School of Medicine , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Shimada","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Osaka University Graduate School of Medicine , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayumi","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Osaka University Graduate School of Medicine , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Osaka University Graduate School of Medicine , Osaka ,","place":["Japan"]},{"name":"Department of Internal Medicine, Japan Community Healthcare Organization Osaka Hospital , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiro","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Osaka University Graduate School of Medicine , Osaka ,","place":["Japan"]},{"name":"Department of Kidney Disease and Hypertension, Osaka General Medical Center , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masamitsu","family":"Senda","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Osaka University Graduate School of Medicine , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Sakaguchi","sequence":"additional","affiliation":[{"name":"Department of Inter-Organ Communication Research in Kidney Disease, Osaka University Graduate School of Medicine , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isao","family":"Matsui","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Osaka University Graduate School of Medicine , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Nakamoto","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fusako","family":"Sera","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shungo","family":"Hikoso","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Sakata","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Isaka","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Osaka University Graduate School of Medicine , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,9,23]]},"reference":[{"key":"2026012114202166000_ehf213507-bib-0001","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/eht386","article-title":"Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis","volume":"35","author":"Damman","year":"2014","journal-title":"Eur Heart J"},{"key":"2026012114202166000_ehf213507-bib-0002","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0735-1097(99)00608-7","article-title":"The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction","volume":"35","author":"Dries","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2026012114202166000_ehf213507-bib-0003","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1161\/01.CIR.102.2.203","article-title":"Renal function, neurohormonal activation, and survival in patients with chronic heart failure","volume":"102","author":"Hillege","year":"2000","journal-title":"Circulation"},{"key":"2026012114202166000_ehf213507-bib-0004","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/heartjnl-2018-313103","article-title":"Cardiac transplantation: indications, eligibility and current outcomes","volume":"105","author":"Bhagra","year":"2019","journal-title":"Heart"},{"key":"2026012114202166000_ehf213507-bib-0005","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","article-title":"Heart disease and stroke statistics-2019 update: a report from the American Heart Association","volume":"139","author":"Benjamin","year":"2019","journal-title":"Circulation"},{"key":"2026012114202166000_ehf213507-bib-0006","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrneph.2016.113","article-title":"Heart failure and kidney dysfunction: epidemiology, mechanisms and management","volume":"12","author":"Schefold","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"2026012114202166000_ehf213507-bib-0007","doi-asserted-by":"crossref","first-page":"F273","DOI":"10.1152\/ajprenal.00195.2005","article-title":"Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure","volume":"290","author":"Costello-Boerrigter","year":"2006","journal-title":"Am J Physiol Physiol"},{"key":"2026012114202166000_ehf213507-bib-0008","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10557-011-6304-x","article-title":"Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase iii, randomized, double-blind, placebo-controlled study (QUEST study)","volume":"25","author":"Matsuzaki","year":"2011","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026012114202166000_ehf213507-bib-0009","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1536\/ihj.18-119","article-title":"Effects of tolvaptan on volume overload in patients with heart failure","volume":"59","author":"Kinugawa","year":"2018","journal-title":"Int Heart J"},{"key":"2026012114202166000_ehf213507-bib-0010","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial","volume":"297","author":"Konstam","year":"2007","journal-title":"JAMA"},{"key":"2026012114202166000_ehf213507-bib-0011","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.jacc.2016.12.035","article-title":"Short-term effects of tolvaptan in patients with acute heart failure and volume overload","volume":"69","author":"Konstam","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026012114202166000_ehf213507-bib-0012","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/ehf2.12088","article-title":"Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure","volume":"3","author":"Jujo","year":"2016","journal-title":"ESC Hear Fail"},{"key":"2026012114202166000_ehf213507-bib-0013","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jjcc.2015.09.020","article-title":"Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure","volume":"67","author":"Kimura","year":"2016","journal-title":"J Cardiol"},{"key":"2026012114202166000_ehf213507-bib-0014","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.jacc.2007.01.091","article-title":"Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction","volume":"49","author":"Udelson","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2026012114202166000_ehf213507-bib-0015","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.cardfail.2013.04.001","article-title":"Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan","volume":"19","author":"Hauptman","year":"2013","journal-title":"J Card Fail"},{"key":"2026012114202166000_ehf213507-bib-0016","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1056\/NEJM197112232852601","article-title":"The natural history of congestive heart failure: the Framingham study","volume":"285","author":"McKee","year":"1971","journal-title":"N Engl J Med"},{"key":"2026012114202166000_ehf213507-bib-0017","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF02089953","article-title":"Clinical and pharmacological investigations of the new saluretic azosemid","volume":"14","author":"Kr\u00fcck","year":"1978","journal-title":"Eur J Clin Pharmacol"},{"key":"2026012114202166000_ehf213507-bib-0018","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1253\/circj.CJ-11-1500","article-title":"Superiority of long-acting to short-acting loop diuretics in the treatment of congestive heart failure","volume":"76","author":"Masuyama","year":"2012","journal-title":"Circ J"},{"key":"2026012114202166000_ehf213507-bib-0019","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1253\/circj.67.384","article-title":"Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure","volume":"67","author":"Yamato","year":"2003","journal-title":"Circ J"},{"key":"2026012114202166000_ehf213507-bib-0020","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"2026012114202166000_ehf213507-bib-0021","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1002\/sim.1815","article-title":"A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials","volume":"23","author":"Royston","year":"2004","journal-title":"Stat Med"},{"key":"2026012114202166000_ehf213507-bib-0022","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1097\/01.CCM.0000296272.68078.6B","article-title":"Diuretics: still the mainstay of treatment","volume":"36","author":"Wang","year":"2008","journal-title":"Crit Care Med"},{"key":"2026012114202166000_ehf213507-bib-0023","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1093\/eurheartj\/ehi696","article-title":"Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis","volume":"27","author":"de Silva","year":"2006","journal-title":"Eur Heart J"},{"key":"2026012114202166000_ehf213507-bib-0024","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0735-1097(03)00765-4","article-title":"Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD)","volume":"42","author":"Domanski","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2026012114202166000_ehf213507-bib-0025","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1007\/s00380-015-0775-9","article-title":"Clinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease","volume":"31","author":"Uemura","year":"2016","journal-title":"Heart Vessels"},{"key":"2026012114202166000_ehf213507-bib-0026","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11897-019-0424-1","article-title":"Diuretic resistance in heart failure","volume":"16","author":"Gupta","year":"2019","journal-title":"Curr Heart Fail Rep"},{"key":"2026012114202166000_ehf213507-bib-0027","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0002-9343(98)00365-9","article-title":"Diuretic treatment and diuretic resistance in heart failure","volume":"106","author":"Kr\u00e4mer","year":"1999","journal-title":"Am J Med"},{"key":"2026012114202166000_ehf213507-bib-0028","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jjcc.2017.10.013","article-title":"Hyponatremia as a surrogate marker for optimal diuretic selection in acute heart failure","volume":"71","author":"Fukushima","year":"2018","journal-title":"J Cardiol"},{"key":"2026012114202166000_ehf213507-bib-0029","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00392-020-01617-w","article-title":"Spot urinary sodium in acute decompensation of advanced heart failure and dilutional hyponatremia: insights from DRAIN trial","volume":"109","author":"Galluzzo","year":"2020","journal-title":"Clin Res Cardiol"},{"key":"2026012114202166000_ehf213507-bib-0030","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/eurheartj\/ehl542","article-title":"Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry","volume":"28","author":"Gheorghiade","year":"2007","journal-title":"Eur Heart J"},{"key":"2026012114202166000_ehf213507-bib-0031","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.amjcard.2012.12.019","article-title":"Hyponatremia and in-hospital mortality in patients admitted for heart failure (from the ATTEND Registry)","volume":"111","author":"Sato","year":"2013","journal-title":"Am J Cardiol"},{"key":"2026012114202166000_ehf213507-bib-0032","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1093\/eurheartj\/ehu065","article-title":"Diuretic response in acute heart failure: clinical characteristics and prognostic significance","volume":"35","author":"Valente","year":"2014","journal-title":"Eur Heart J"},{"key":"2026012114202166000_ehf213507-bib-0033","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/ejhf.170","article-title":"Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome--an analysis from RELAX-AHF","volume":"16","author":"Voors","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026012114202166000_ehf213507-bib-0034","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41440-018-0169-3","article-title":"Renoprotective effects of tolvaptan in hypertensive heart failure rats depend on renal decongestion","volume":"42","author":"Chiba","year":"2019","journal-title":"Hypertens Res"},{"key":"2026012114202166000_ehf213507-bib-0035","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jacc.2008.05.068","article-title":"Importance of venous congestion for worsening of renal function in advanced decompensated heart failure","volume":"53","author":"Mullens","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026012114202166000_ehf213507-bib-0036","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.ejheart.2007.05.010","article-title":"Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction","volume":"9","author":"Damman","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"2026012114202166000_ehf213507-bib-0037","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/ejhf.630","article-title":"Right ventricular dysfunction in heart failure with preserved ejection fraction: a systematic review and meta-analysis","volume":"18","author":"Gorter","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026012114202166000_ehf213507-bib-0038","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1536\/ihj.54.98","article-title":"Renoprotective effect of vasopressin v2 receptor antagonist tolvaptan in Dahl rats with end-stage heart failure","volume":"54","author":"Ishikawa","year":"2013","journal-title":"Int Heart J"},{"key":"2026012114202166000_ehf213507-bib-0039","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.cardfail.2011.08.005","article-title":"A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction","volume":"17","author":"Udelson","year":"2011","journal-title":"J Card Fail"},{"key":"2026012114202166000_ehf213507-bib-0040","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s10741-015-9503-x","article-title":"The short-term and long-term effects of tolvaptan in patients with heart failure: a meta-analysis of randomized controlled trials","volume":"20","author":"Xiong","year":"2015","journal-title":"Heart Fail Rev"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.13507","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.13507","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/8\/6\/4904\/65570170\/eschf_8_6_4904.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/8\/6\/4904\/65570170\/eschf_8_6_4904.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:24:44Z","timestamp":1769023484000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/8\/6\/4904\/8343887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,23]]},"references-count":40,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,9,23]]},"published-print":{"date-parts":[[2021,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.13507","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12]]},"published":{"date-parts":[[2021,9,23]]},"assertion":[{"value":"2021-02-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}